OncoGenex (NASDAQ:OGXI) is a small-cap biotech company with multiple potential blockbusters in its pipeline. The company will soon report data from the first of three ongoing Phase III trials. Its flagship drug, OGX-011, is designed to complement conventional chemotherapy by knocking down the specific molecular mechanisms tumor cells use to stay alive. Strong data from multiple successful Phase II trials and other clinical evidence indicate a high probability of success in Phase III. Based on approval milestones and sales goals, OGXI stands to receive up to $370 million from its partner Teva Pharmaceuticals, plus additional sales royalties. On the basis of these payments alone, OGXI is substantially undervalued. But what's really exciting is the generalizability of OGX-011 -...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|